Cervomed Inc

This non-binding management proposal asks stockholders to approve the compensation paid to the Company’s named executive officers for 2025 as disclosed in the Proxy Statement. Management frames the proposal as an overall endorsement of the Company’s pay philosophy and practices—designed to attract and retain talent, align executives’ incentives with long-term stockholder value, and reward achievement of corporate and individual performance goals. The Compensation Committee administers the program, uses peer benchmarking and consultant input, and structures pay as a mix of base salary, annual cash incentives tied to performance, and long-term equity awards vesting over multi-year periods to promote retention. The advisory vote is nonbinding under law, but the Board commits to consider the outcome when making future compensation decisions and to engage with stockholders on governance and pay-related concerns. Contextually, the Company reported significant equity activity in recent years (including option grants and plan amendments) and is preparing for potential growth and a Phase 3 program, making retention incentives material to strategy execution. The Board’s recommendation for a “For” vote is justified by its view that the disclosed practices support pay-for-performance, align management and stockholder interests, and contain governance features (e.g., clawback, limits on repricing) intended to protect stockholders. The proposal should be evaluated relative to the Company’s compensation disclosures, equity dilution practices, and recent corporate events (merger history, hiring, potential headcount increases) that affect incentive needs. Given the advisory nature, investors will weigh whether the mix of cash and equity, vesting schedules, severance/change-in-control protections, and use of consultants appropriately balance retention and performance alignment without excessive risk or dilution.

This management proposal seeks shareholder approval to amend the 2025 Equity Incentive Plan to increase the share reserve by 2,000,000 shares (from 800,000 to 2,800,000). Management argues the increase is necessary to support anticipated headcount growth, equity grants tied to a planned Phase 3 clinical program, and general hiring and retention needs as the company advances its pipeline. The proposal asks shareholders to accept the specific amended Section 4.1 language increasing the Base Amount and preserving customary adjustment and transfer mechanics. The Board emphasizes governance protections retained in the plan — including limits on individual awards, no repricing without stockholder approval, no discounted options, clawback provisions, and administration by an independent committee — to mitigate dilution and align incentives with stockholder interests. The recommendation highlights that the increased reserve is expected to last several years under current plans and that the Compensation Committee relied on benchmarking and an independent consultant in assessing likely grant volume. Investors should weigh the incremental dilution (company estimates potential dilution rising from ~15.7% to ~28.6% on a fully awarded basis) against the strategic necessity of equity incentives to recruit and retain talent for clinical development. The Board recommends a “For” vote because it views the amended reserve as essential to execute near-term clinical and corporate plans while preserving plan features intended to protect stockholders and maintain appropriate governance oversight.